Newer approaches to the pharmacological management of heart failure

Current Opinion in Anaesthesiology

Volumn 19, Issue 1, 2006, Pages 75-81

  Rauch, Helmut ^a   Motsch, Johann ^a   Böttiger, Bernd W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain natriuretic peptide; Calcium sensitizer; Endothelin receptor blocker; Heart failure; Nitric oxide synthase inhibitor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM SENSITIZER; CATECHOLAMINE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXIMONE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; N(G) NITROARGININE METHYL ESTER; NESIRITIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; TEZOSENTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

CARDIOGENIC SHOCK; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FORWARD HEART FAILURE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INTESTINE PERFUSION; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CALCIUM SIGNALING; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; ENDOTHELINS; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; NATRIURETIC PEPTIDE, BRAIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PYRIDAZINES; PYRIDINES; TETRAZOLES;

EID: 33144471134     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000192781.62892.c3     Document Type: Review

References (53)

1. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.
2. American Heart Association. Heart Disease and Stroke Statistics: 2004 update. Dallas, TX: American Heart Association; 2003.
3. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilizitation Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39:60-69.
4. Redfield MM. Heart failure: an epidemic of uncertain proportions. N Engl J Med 2002; 347:1442-1444.
5. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104:2996-3007.
6. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-1560.
7. Sanborn TA, Feldman T. Management strategies for cardiogenic shock. Curr Opin Cardiol 2004; 19:608-612. This review presents a short survey on the role of nitric oxide in the pathophysiology of cardiogenic shock and the therapeutic approach that can be derived from it.
8. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators: should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999; 341:625-634.
9. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 2004; 24:1366-1384. An excellent, very thorough and critically weighed update on levosimendan.
10. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 2002; 4:515-529.
11. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 2004; 19:254-263. A clearly structured summary of current treatments for AHF, with special emphasis on evidence-based strategies.
12. Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol 1995; 26 (Suppl 1):S77-S84.
13. Lilleberg J, Ylönen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38:80-84. This meta-analysis of clinical studies confirms experimental work on the lack of an arrhythmogenic effect of levosimendan.
14. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27:1859-1866.
15. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486:67-74.
16. Pataricza J, Krassoi I, Hohn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17:115-121.
17. Schwinger RHG, Brixius K. Sensitization of the myofilaments and its implication for treatment in human heart failure [in German]. Deutsch Med Wochenschr 2005; 130:969-973. Comprehensive and critically weighed summary of the effects of calcium sensitizers commonly used in clinical practice.
18. Schwarte LA, Picker O, Bornstein SR, et al. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005; 33:135-142. With all its limitations, the findings from this experimental study offer suggestions for why mortality is decreased by levosimendan treatment as compared with conventional inodilatory drugs.
19. Coopersmith M. Levosimendan and gut mucosal blood flow: not all inotropes are created equal. Crit Care Med 2005; 33:246-247.
20. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68:807-812.
21. Eriksson O, Pollesello P, Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 2004; 44:316-321. This experimental study is of interest because, in contrast to most other investigations, oxygen consumption was found to be increased under levosimendan treatment, albeit under conditions that allow only very limited conclusions to be drawn for the clinical setting.
22. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111:1504-1509. The findings from this experimental study in 10 patients support a special role for levosimendan among the positively inotropic medications. The study was conducted in patients without decompensated heart failure, however, and coronary arteries with significant stenoses were excluded from the analysis.
23. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432.
24. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360:196-202.
25. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6:501-508. This review presents a meta-analysis of large, multicenter studies carried out on the use of levosimendan in patients with heart failure as compared with placebo and dobutamine.
26. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005; 26:384-416.
27. Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005; 95: 768-771. This work demonstrates the synergistic effects of β-inotropic drugs and levosimendan, albeit in cardiology patients with chronic heart failure.
28. Labriola C, Siro-Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42:204-211. For all its weaknesses, this is the only study published in the review period that used a prospective design to examine perioperative levosimendan treatment in patients with cardiac failure.
29. Plöchl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004; 32:471-475.
30. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45:704-708.
31. 2+ sensitizer levosimendan [in German]. Med Klin 2004; 99:742-746.
32. Braun JP, Schneider M, Dohmen P, Döpfmer U. Successful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J Cardiothorac Vasc Anesth 2004; 18:772-774.
33. Braun JP, Schneider M, Kastrup M, Liu J. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 2004; 26:228-230.
34. Benlolo S, Lefoll C, Katchatouryan V, et al. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 2004; 98:822-824.
35. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31:638-644. This study shows a significant benefit of calcium sensitization for patients with septic myocardial failure. The pronounced vasodilation in these patients, however, may represent possible disadvantages of the treatment.
36. Cheng JWM. Tezosentan in the management of decompensated heart failure. Cardiol Rev 2005; 13:28-34. Comprehensive and critical evaluation of the concept of endothelin receptor antagonism in the treatment of heart failure.
37. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108:2184-2190.
38. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42:140-147.
39. O'Connor CM, Gattis WA, Adams KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol 2003; 41:1452-1457.
40. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol 2003; 41:204-210.
41. Cotter G, Kaluski E, Stangl K, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004; 6:601-609. Here, explanations are provided for why large and elaborate studies have not yet shown tezosentan treatment to be superior to conventional therapeutic strategies.
42. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005; 20:201-210.
43. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:317-322.
44. Burger AJ, Silver MA. Nesiritide in acute heart failure. And author's reply. Lancet 2003; 362:998-999.
45. De Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004; 125:652-668.
46. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005; 23:327-331. This study demonstrates an interesting aspect of nesiritide: blood pressure is reduced preferentially in patients with elevated baseline levels, which is considered to indicate a self-limiting effect of the drug.
47. Samuels LE, Holmes EC, Letwin L. Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 2004; 128:627-629. An observational study on the use of nesiritide after surgery in heart surgery patients, albeit with a small number of patients and without clearly defined end-points.
48. Sinha AM, Breithardt OA, Schmid M, Stellbrink C. Brain natriuretic peptide release in cardiac surgery patients. Thorac Cardiovasc Surg 2005; 53:138-143. A useful update on brain natriuretic peptide for diagnosis and therapy in the perioperative setting.
49. Feldman DS, Sun B. Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting. Heart Fail Rev 2004; 9:209-216. This review provides practical information on nesiritide dosages in heart surgery patients after surgery.
50. Geppert A, Huber K. Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Curr Opin Crit Care 2004; 10:347-353.
51. Lehmann A, Boldt J. New pharmacologic approaches for the perioperative treatment of ischemic cardiogenic shock. J Cardiothorac Vasc Anesth 2005; 19:97-108. Comprehensive study on the state-of-the-art of pharmacotherapy for ischemic cardiogenic shock.
52. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock. Eur Heart J 2003; 24:1287-1295.
53. Menon V. Cardiogenic shock: have we really found the magic potion? Eur Heart J 2003; 24:1279-1281.